JP2019534685A - 免疫療法マーカー及びその使用 - Google Patents
免疫療法マーカー及びその使用 Download PDFInfo
- Publication number
- JP2019534685A JP2019534685A JP2019510972A JP2019510972A JP2019534685A JP 2019534685 A JP2019534685 A JP 2019534685A JP 2019510972 A JP2019510972 A JP 2019510972A JP 2019510972 A JP2019510972 A JP 2019510972A JP 2019534685 A JP2019534685 A JP 2019534685A
- Authority
- JP
- Japan
- Prior art keywords
- data
- signature
- apobec
- omics
- immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/20—Heterogeneous data integration
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Primary Health Care (AREA)
- Bioethics (AREA)
Abstract
【選択図】図1
Description
Claims (31)
- 癌の免疫療法の治療アウトカムを予測する方法であって、
患者の腫瘍からオミクスデータを入手する段階と、
オミクスデータにおいてAPOBECシグネチャー及びPOLEシグネチャーの内の少なくとも1種を特定する段階と、
オミクスデータからチェックポイント阻害に関連する複数の遺伝子の発現を定量化する段階と、
オミクスデータからMSIステータスを確認する段階と、
APOBECシグネチャー及び/又はPOLEシグネチャー、確認された複数の遺伝子の発現量、及びMSIステータスを用いて、癌の免疫療法の治療アウトカムの予測を示す患者プロファイルを更新又は生成する段階とを含む方法。 - 少なくとも1種の追加の変異シグネチャーを特定する段階を更に含む、請求項1に記載の方法。
- 追加の変異シグネチャーが、カタエギスシグネチャー、Ig遺伝子高頻度変異シグネチャー、喫煙変異シグネチャー、加齢性変異シグネチャー、UV光変異シグネチャー、又はDNA MMR関連変異シグネチャーである、請求項2に記載の方法。
- 免疫療法が、ワクチン成分、細胞ベースの成分及びチェックポイント阻害成分の内の少なくとも2種を含む、先行請求項のいずれかに記載の方法。
- オミクスデータが、全ゲノム配列決定データ、RNA配列決定データ、転写レベルデータ、cfDNA配列データ、cfRNA配列データ、及びプロテオミクスデータの内の少なくとも1種を含む、先行請求項のいずれかに記載の方法。
- オミクスデータが、全ゲノム配列決定データ、RNA配列決定データ、転写レベルデータ、cfDNA配列データ、cfRNA配列データ、及びプロテオミクスデータの内の少なくとも2種を含む、先行請求項のいずれかに記載の方法。
- オミクスデータが、同じ患者の健康な組織由来のオミクスデータに対して基準化されている、先行請求項のいずれかに記載の方法。
- APOBECシグネチャーは、TpCpS→TpKpS、TpCpN→TpApN、及びTpCpW→TpKpWから成る群から選択され、SはC又はGであり、KはG又はTであり、NはC又はG又はA又はTであり、WはA又はTである、先行する請求項のいずれかに記載の方法。
- POLEシグネチャーが、TpCpT→TpApT及びTpTpT→TpGpTから成る群から選択される、先行請求項のいずれかに記載の方法。
- チェックポイント阻害に関連する遺伝子が、IDO、TDO、TIM3、CD40、LAG3、PD−L1、PD−L2、CTLA4、PD1及びIL2から成る群から選択される、先行請求項のいずれかに記載の方法。
- 複数の遺伝子が少なくとも5種の遺伝子である、請求項10に記載の方法。
- MSIステータスが、患者のMHC複合体に結合するネオエピトープの量から推測される、先行請求項のいずれかに記載の方法。
- 癌の免疫療法の治療アウトカムの予測が定性的予測である、先行請求項のいずれかに記載の方法。
- APOBECシグネチャー及び/又はPOLEシグネチャーの存在が好ましい治療アウトカムを示す、請求項13に記載の方法。
- 陽性MSIが好ましい治療アウトカムを示す、請求項13に記載の方法。
- チェックポイント阻害に関連する複数の遺伝子の過剰発現が好ましい治療アウトカムを示す、請求項13に記載の方法。
- Th1T細胞活性化、細胞傷害性T細胞活性化、及びナチュラルキラー細胞活性化の経路活性を確認する段階を更に含む、先行請求項のいずれかに記載の方法。
- 免疫療法が、ワクチン成分、細胞ベースの成分及びチェックポイント阻害成分の内の少なくとも2種を含む、請求項1に記載の方法。
- オミクスデータが、全ゲノム配列決定データ、RNA配列決定データ、転写レベルデータ、cfDNA配列データ、cfRNA配列データ、及びプロテオミクスデータの内の少なくとも1種を含む、請求項1に記載の方法。
- オミクスデータが、全ゲノム配列決定データ、RNA配列決定データ、転写レベルデータ、cfDNA配列データ、cfRNA配列データ、及びプロテオミクスデータの内の少なくとも2種を含む、請求項1に記載の方法。
- オミクスデータが、同じ患者の健康な組織由来のオミクスデータに対して基準化されている、請求項1に記載の方法。
- APOBECシグネチャーが、TpCpS→TpKpS、TpCpN→TpApN、及びTpCpW→TpKpWから成る群から選択され、SがC又はGであり、KがG又はTであり、NがC又はG又はA又はTであり、WがA又はTである、請求項1に記載の方法。
- POLEシグネチャーが、TpCpT→TpApT及びTpTpT→TpGpTから成る群から選択される、請求項1に記載の方法。
- チェックポイント阻害に関連する遺伝子が、IDO、TDO、TIM3、CD40、LAG3、PD−L1、PD−L2、CTLA4、PD1及びIL2から成る群から選択される、請求項1に記載の方法。
- 複数の遺伝子が少なくとも5種の遺伝子である、請求項24に記載の方法。
- MSIステータスが、患者のMHC複合体に結合するネオエピトープの量から推測される、請求項1に記載の方法。
- 癌の免疫療法の治療アウトカムの予測が定性的予測である、請求項1に記載の方法。
- APOBECシグネチャー及び/又はPOLEシグネチャーの存在が好ましい治療アウトカムを示す、請求項27に記載の方法。
- 陽性MSIが好ましい治療アウトカムを示す、請求項27に記載の方法。
- チェックポイント阻害に関連する複数の遺伝子の過剰発現が好ましい治療アウトカムを示す、請求項27に記載の方法。
- Th1T細胞活性化、細胞傷害性T細胞活性化、及びナチュラルキラー細胞活性化の経路活性を確認する段階を更に含む、請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662379700P | 2016-08-25 | 2016-08-25 | |
US62/379,700 | 2016-08-25 | ||
PCT/US2017/048629 WO2018039567A1 (en) | 2016-08-25 | 2017-08-25 | Immunotherapy markers and uses therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019534685A true JP2019534685A (ja) | 2019-12-05 |
JP6995842B2 JP6995842B2 (ja) | 2022-01-17 |
Family
ID=61246344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019510972A Active JP6995842B2 (ja) | 2016-08-25 | 2017-08-25 | 免疫療法マーカー及びその使用 |
Country Status (9)
Country | Link |
---|---|
US (2) | US11875877B2 (ja) |
EP (1) | EP3500966B1 (ja) |
JP (1) | JP6995842B2 (ja) |
KR (2) | KR20190038935A (ja) |
CN (1) | CN109937452B (ja) |
AU (1) | AU2017315468B2 (ja) |
CA (1) | CA3034771C (ja) |
SG (1) | SG11201901432YA (ja) |
WO (1) | WO2018039567A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11875877B2 (en) | 2016-08-25 | 2024-01-16 | Nantomics, Llc | Immunotherapy markers and uses therefor |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200362418A1 (en) * | 2017-10-02 | 2020-11-19 | Curematch, Inc. | Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns |
WO2019095017A1 (en) * | 2017-11-17 | 2019-05-23 | Gmdx Co Pty Ltd | Systems and methods for predicting the efficacy of cancer therapy |
TWI816603B (zh) * | 2018-04-23 | 2023-09-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
CN108796077B (zh) * | 2018-05-30 | 2021-11-09 | 朱运峰 | 在cfDNA中检测胞嘧啶脱氨酶及相关分子基因修饰差异的引物对组及试剂盒 |
US20210189505A1 (en) * | 2018-08-23 | 2021-06-24 | Nantcell, Inc. | Assessing microsatellite instability by liquid biopsy |
WO2020091944A1 (en) * | 2018-10-31 | 2020-05-07 | Nantomics, Llc | Genomic and immune infiltration differences between msi and mss gi tumors |
JP2022521792A (ja) * | 2019-02-27 | 2022-04-12 | ネクター セラピューティクス | 癌を治療するための免疫療法的併用 |
GB201908565D0 (en) * | 2019-06-14 | 2019-07-31 | Cray Innovation Ab | Method of stratifying subjects into sub-groups for therapeutic treatment |
CN111883203B (zh) * | 2020-07-03 | 2023-12-29 | 上海厦维医学检验实验室有限公司 | 用于预测pd-1疗效的模型的构建方法 |
WO2022099004A1 (en) * | 2020-11-06 | 2022-05-12 | The General Hospital Corporation | Methods for characterizing biological samples |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2518569C (en) | 2003-03-10 | 2011-11-15 | Expression Pathology, Inc. | Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
US8841068B2 (en) * | 2005-02-11 | 2014-09-23 | University Of Rochester | Human immunodeficiency virus antiviral screening assay involving the detection of CEM15 expression |
WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
US10192641B2 (en) | 2010-04-29 | 2019-01-29 | The Regents Of The University Of California | Method of generating a dynamic pathway map |
WO2011139345A2 (en) | 2010-04-29 | 2011-11-10 | The Regents Of The University Of California | Pathway recognition algorithm using data integration on genomic models (paradigm) |
KR102042253B1 (ko) | 2010-05-25 | 2019-11-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Bambam:고처리율 서열분석 데이터의 병렬 비교 분석 |
US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
KR20140147797A (ko) * | 2011-06-27 | 2014-12-30 | 더 잭슨 래보라토리 | 암 및 자가면역 질환의 치료 방법 및 조성물 |
US20130086705A1 (en) * | 2011-09-29 | 2013-04-04 | The Regents Of The University Of California | Compositions and methods for reducing and detecting viral infection |
US9091651B2 (en) | 2011-12-21 | 2015-07-28 | Integrated Diagnostics, Inc. | Selected reaction monitoring assays |
WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
EP2914750B1 (en) | 2012-11-05 | 2018-04-18 | GMDx Co Pty Ltd | Methods for determining the cause of somatic mutagenesis |
WO2014080381A1 (en) * | 2012-11-26 | 2014-05-30 | Ecole Polytechnique Federale De Lausanne (Epfl) | Colorectal cancer classification with differential prognosis and personalized therapeutic responses |
EP3065772A4 (en) * | 2013-11-05 | 2017-09-13 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
CN107002132A (zh) | 2014-11-14 | 2017-08-01 | 液体基因有限公司 | 循环无细胞rna用于诊断和/或监测癌症的用途 |
MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
US10975442B2 (en) * | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
WO2017004165A1 (en) | 2015-06-29 | 2017-01-05 | Regents Of The University Of Minnesota | Apobec3b mutagenesis and immunotherapy |
US20180185302A1 (en) | 2015-06-30 | 2018-07-05 | Regents Of The University Of Minnesota | Methods for downregulating apobec3b |
US11225690B2 (en) | 2015-08-26 | 2022-01-18 | Gmdx Co Pty Ltd | Methods of detecting cancer recurrence |
KR20180087244A (ko) | 2015-10-12 | 2018-08-01 | 난토믹스, 엘엘씨 | 체크포인트 억제제에 대한 감도를 예측하는 msi 및 네오에피토프를 발견하기 위한 위한 시스템, 조성물 및 방법 |
CA3005119A1 (en) | 2015-11-19 | 2017-05-26 | Myriad Genetics, Inc. | Signatures for predicting cancer immune therapy response |
KR20190038608A (ko) | 2016-08-03 | 2019-04-08 | 난토믹스, 엘엘씨 | 다사티닙 반응 예측 모델들 및 이를 위한 방법들(dasatinib response prediction models and methods therefor) |
SG11201901432YA (en) | 2016-08-25 | 2019-03-28 | Nantomics Llc | Immunotherapy markers and uses therefor |
-
2017
- 2017-08-25 SG SG11201901432YA patent/SG11201901432YA/en unknown
- 2017-08-25 JP JP2019510972A patent/JP6995842B2/ja active Active
- 2017-08-25 US US16/327,802 patent/US11875877B2/en active Active
- 2017-08-25 EP EP17844492.3A patent/EP3500966B1/en active Active
- 2017-08-25 WO PCT/US2017/048629 patent/WO2018039567A1/en active Search and Examination
- 2017-08-25 KR KR1020197008366A patent/KR20190038935A/ko active Application Filing
- 2017-08-25 KR KR1020207000181A patent/KR20200003294A/ko not_active Application Discontinuation
- 2017-08-25 CN CN201780052115.7A patent/CN109937452B/zh active Active
- 2017-08-25 AU AU2017315468A patent/AU2017315468B2/en active Active
- 2017-08-25 CA CA3034771A patent/CA3034771C/en active Active
-
2023
- 2023-11-10 US US18/506,554 patent/US20240079089A1/en active Pending
Non-Patent Citations (4)
Title |
---|
CANCER TREAT. REV., vol. 48, JPN6020033670, June 2016 (2016-06-01), pages 61 - 68, ISSN: 0004340811 * |
CARCINOGENESIS, vol. 34, JPN6020033674, 2013, pages 2240 - 2243, ISSN: 0004340813 * |
LEUKEMIA, vol. 28, JPN6020033676, 2014, pages 1929 - 1932, ISSN: 0004340814 * |
SCI. REP., vol. Vol. 6:27702, JPN6020033672, June 2016 (2016-06-01), pages 1 - 7, ISSN: 0004340812 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11875877B2 (en) | 2016-08-25 | 2024-01-16 | Nantomics, Llc | Immunotherapy markers and uses therefor |
Also Published As
Publication number | Publication date |
---|---|
AU2017315468B2 (en) | 2020-02-13 |
CN109937452A (zh) | 2019-06-25 |
US20240079089A1 (en) | 2024-03-07 |
CN109937452B (zh) | 2023-04-11 |
US20190237196A1 (en) | 2019-08-01 |
EP3500966A4 (en) | 2020-05-06 |
CA3034771A1 (en) | 2018-03-01 |
EP3500966A1 (en) | 2019-06-26 |
JP6995842B2 (ja) | 2022-01-17 |
KR20190038935A (ko) | 2019-04-09 |
AU2017315468A1 (en) | 2019-03-28 |
CA3034771C (en) | 2021-10-26 |
US11875877B2 (en) | 2024-01-16 |
SG11201901432YA (en) | 2019-03-28 |
EP3500966B1 (en) | 2021-04-21 |
KR20200003294A (ko) | 2020-01-08 |
WO2018039567A1 (en) | 2018-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6995842B2 (ja) | 免疫療法マーカー及びその使用 | |
US20230307090A1 (en) | Systems, Compositions, And Methods For Discovery Of MSI And Neoepitopes That Predict Sensitivity To Checkpoint Inhibitors | |
US11361841B2 (en) | High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies | |
JP7073254B2 (ja) | 癌における「免疫チェックポイント介入」 | |
CN110214275B (zh) | 肿瘤抗原性加工和呈递 | |
JP7034931B2 (ja) | ネオエピトープのウイルス送達のための改善された組成物および方法ならびにその使用 | |
KR101945093B1 (ko) | 다중 종양 및 생식세포 유전자 엑솜에 걸친 분자 프로파일의 종합 분석을 위한 시스템 및 방법 | |
Pagadala et al. | Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response | |
Vos et al. | Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial | |
JP2023543838A (ja) | 膀胱がん又は腎臓がん対象者の転帰の予測 | |
US20210398612A1 (en) | Detecting tumor mutation burden with rna substrate | |
JP2023524048A (ja) | 癌の免疫療法のための複合バイオマーカー | |
CN111670255A (zh) | 来自液体瘤和实体瘤的bam特征及其用途 | |
US20240112813A1 (en) | Methods and systems for annotating genomic data | |
US20210375395A1 (en) | Omics Detection of Nonhomologous End Joining Repair Site Signatures | |
Yan et al. | DCBLD1 is a Prognostic Biomarker and Correlated with an Immunosuppressive Microenvironment in Pan-Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20190417 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200803 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200803 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200826 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210202 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20210218 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210506 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211005 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211215 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6995842 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |